Why Isn't My T3 Working? The Six Research-Community Explanations for T3 Non-Response

T3 non-response is one of the most consistently reported frustrations in bioenergetic research-community discussion of thyroid optimization. A research subject starts an SR-T3 protocol expecting the well-documented symptom resolution - rising basal body temperature toward 98.6°F, improved energy, cognitive clarity, resolution of the cold-hands-and-feet pattern - and does not get it. Or gets a partial response that stalls. Or sees initial improvement followed by a plateau that no additional T3 dose seems to move.

The natural question is: why? Is the T3 not working? Is the dose wrong? Is there something blocking it?

The bioenergetic research community has worked through enough of these non-response patterns to produce a reasonably coherent diagnostic framework. There are six distinct mechanism-based explanations for T3 non-response, each with a different root cause and a different corrective approach. Understanding which explanation applies to a given pattern is the prerequisite for resolving it.

This article covers each of the six explanations in detail - the mechanism, the diagnostic signal, and the research-community approach for each - followed by a decision-tree framework for working through them systematically.

Research framing. This article reviews T3 non-response patterns from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our research legality FAQ page for full terms.

Explanation 1: Dose Too Low

The simplest explanation for T3 not working is that the dose being used is not sufficient to produce the response being sought. This explanation is more common than most research subjects initially assume, because the mainstream endocrinology context around T3 doses makes even modest amounts seem high.

In mainstream clinical endocrinology, T3 supplementation - when used at all - is typically administered at 5-25 mcg/day. This range reflects a conservative approach calibrated for patients with a functional HPT axis and no particular target beyond bringing TSH into range. The bioenergetic research framework, particularly the Wilson's WT3 protocol, operates on a different endpoint: basal body temperature reaching 98.6°F as a proxy for adequate peripheral tissue T3 activity. These two endpoints - TSH in range vs. temperature at target - often require very different doses.

The Wilson's WT3 cyclic protocol commonly reaches 45-90 mcg/day in total divided doses before research subjects achieve the temperature endpoint. The 7.5-15 mcg starting doses used in the early titration steps are entry points, not treatment doses. A research subject who has titrated to 22.5 mcg total daily and stopped, citing concern about going higher, may be stopping before the dose that would actually produce the response they are looking for.

The dose ceiling fear that drives early stoppage is understandable given the mainstream framing. Anything above 25 mcg/day is labeled "high dose" in most endocrinology literature, and the cardiovascular and bone-density concerns associated with sustained TSH suppression are real. The research-community response to this concern is not to disregard it but to reframe it: the WT3 protocol is cyclic, not sustained. The dose-escalation phase is followed by a taper and a period of endogenous recovery. The goal is not indefinite high-dose T3 but a time-limited titration to a target temperature endpoint, followed by taper and reassessment.

The diagnostic question for Explanation 1 is direct: has the research subject actually titrated to symptom resolution or to clear adverse effects, or has titration stopped because the dose felt high relative to mainstream benchmarks? If the answer is the latter - if there are no adverse effects, no cardiovascular signals, no adverse temperature response, but simply a number that looks large compared to conventional prescribing - the most likely explanation for non-response is insufficient dose.

The correct approach is to continue titration in the standard Wilson's increment structure, using the body temperature tracking protocol and the adverse effect monitoring framework detailed in the SR-T3 dosing troubleshooting guide. T3 non-response from underdosing resolves when the dose reaches the level that actually produces the target response. The tricky part is that this level is highly individual and cannot be predicted from body weight, TSH level, or any other easily-measured variable. The temperature endpoint is the guide.

Explanation 2: Reverse T3 Dominance

Reverse T3 (rT3) dominance is the best-known mechanism-based explanation for T3 non-response and the one most extensively discussed in the research community. It operates through a receptor-competition pathway: rT3 is structurally similar enough to T3 that it binds thyroid hormone receptor sites, but it is metabolically inert - it does not activate the receptor. Elevated rT3 therefore acts as a competitive inhibitor, occupying receptor sites that active T3 would otherwise bind and reducing the effective signaling of whatever T3 is present.

The deiodinase mechanism that produces rT3 is well-characterized. DIO3 (type 3 deiodinase) removes iodine from the inner ring of T4, producing rT3 rather than active T3. Under physiological stress - inflammation, elevated cortisol, caloric restriction, chronic illness - DIO3 activity increases and DIO1/DIO2 activity decreases. The net effect is a shift in the T4 processing balance: less T4 goes toward active T3 production, more goes toward rT3. As rT3 accumulates, the ratio of free T3 to rT3 falls, and receptor-level signaling degrades even when serum free T3 looks numerically normal.

The diagnostic signal for rT3 dominance is distinctive. Research subjects with this pattern often have free T3 in the upper-normal range - the T3 is measurably present - but report none of the symptom resolution that should accompany that free T3 level. Body temperature fails to rise appropriately despite T3 dose increases. Energy does not improve. The standard panel looks adequate but the clinical response is absent. This disconnect - adequate T3 supply with no T3 effect - points toward receptor-level blockade rather than T3 deficiency.

The lab confirmation is the FT3:rT3 ratio. The research-community threshold most frequently cited is an FT3:rT3 ratio below 20 (with FT3 in pg/mL and rT3 in ng/dL) as indicative of rT3 dominance, though specific cutoffs vary by source. A ratio in this range confirms that rT3 accumulation is sufficient to substantially impair effective T3 signaling. For a full technical review of the FT3:rT3 ratio - how to calculate it, what values indicate dominance, and how the WT3 protocol addresses rT3 clearance - see the reverse T3 complete guide.

The research-community approach for rT3 dominance is the standard Wilson's WT3 cyclic escalation: high-dose SR-T3 administered in every-12-hour sustained-release doses, titrated to the temperature endpoint, suppressing the HPT axis sufficiently to reduce the T4 substrate available for DIO3 to convert to rT3. When exogenous T3 is the dominant thyroid input and T4 is suppressed, rT3 production falls. The receptor sites previously occupied by rT3 clear over time, allowing the administered T3 to achieve normal binding and signaling. Three consecutive weeks at the target temperature endpoint, followed by taper, is the standard WT3 protocol structure for clearing rT3 dominance.

The diagnostic question for Explanation 2: has the FT3:rT3 ratio been measured? If not, measuring it is the first step before proceeding to any other explanation.

Explanation 3: The T3 to T2 Conversion Bottleneck

This is the explanation that the research community has identified most recently - and it is the one that most directly explains a specific pattern: T3 non-response that persists even when rT3 is normal and free T3 is adequate.

The mechanism requires understanding one additional step in the thyroid hormone cascade that mainstream endocrinology rarely discusses. T3 is not the terminal product of thyroid hormone metabolism. Once T3 is present - whether produced from T4 conversion or delivered as exogenous SR-T3 - the deiodinase system continues processing it. The primary downstream pathway involves DIO1 (type 1 deiodinase) removing the 3'-iodine from T3 to produce 3,3'-T2 (3,3'-diiodothyronine), the main catabolic product of T3 in peripheral tissues. More metabolically significant is 3,5-T2 (3,5-diiodothyronine), the isomer that operates through an entirely different biological pathway than T3 itself.

3,5-T2 binds directly to subunit Va of cytochrome c oxidase - Complex IV of the mitochondrial electron transport chain - and acutely elevates aerobic respiration without requiring nuclear receptor activation or protein synthesis. This is the mechanism established by Goglia and colleagues in the 1994 FEBS Letters paper and supported by subsequent replication. T3's primary mechanism is genomic: it binds nuclear TRalpha and TRbeta receptors, drives gene transcription, and produces metabolic effects over a 6-48 hour window. T2's mechanism is rapid and direct: cytochrome c oxidase activation measurable within minutes, independent of gene transcription. These are not interchangeable pathways. A research subject with adequate T3 at nuclear receptors may still have inadequate mitochondrial activation at the Complex IV level if T3-to-T2 conversion is impaired.

The critical point is why T3-to-T2 conversion is impaired in exactly the research subjects who most need T3 protocols. DIO1 - the enzyme primarily responsible for processing T3 into diiodothyronine products - is a selenoprotein. Its catalytic activity requires selenium in the form of selenocysteine at the active site. Selenium deficiency degrades DIO1 activity. The same cytokines that suppress DIO1 during T4-to-T3 conversion (IL-6, TNF-alpha, IL-1beta) continue suppressing DIO1 in the T3-to-T2 processing step. Elevated cortisol drives DIO3 dominance, reducing the T4 substrate available for DIO1 while increasing rT3 production - and the same DIO imbalance that produces rT3 dominance reduces DIO1's capacity to process T3 downstream. The conditions creating the original need for a T3 protocol are precisely the conditions that block the T3-to-T2 conversion step.

The clinical signal is the T3 plateau pattern: a research subject on an established T3 protocol whose free T3 is in the upper-normal range, whose rT3 has been normalized, whose TSH is appropriately suppressed - but whose body temperature stabilizes at 97.8-98.0°F rather than 98.6°F, whose energy remains persistently flat, and for whom additional T3 dose increases produce no further response. The nuclear receptor pathway appears adequately served by the existing T3 dose. What is not adequately restored is the mitochondrial activation pathway that depends specifically on T2 reaching the cytochrome c oxidase binding site. The genomic signaling channel is open; the mitochondrial energy channel is blocked at the conversion step.

This pattern - adequate T3, normalized rT3, persistent metabolic underperformance - is the diagnostic hallmark of the T3-to-T2 conversion bottleneck. For a full mechanistic treatment of this pathway, including the deiodinase overlap between both conversion steps, the cytochrome c oxidase binding mechanism, and the rationale for T3+T2 combined supplementation, see the T3-to-T2 conversion problem centerpiece.

The research-community solution for the T3-to-T2 conversion bottleneck is direct supplementation of both T3 and T2, bypassing the impaired conversion step entirely rather than attempting to force more substrate through a broken enzyme. The Wilson's T3+T2 Combo formulates T3 and T2 at a 1:1 mcg ratio in sustained-release capsules, ensuring that both the nuclear receptor signaling pathway (T3) and the mitochondrial cytochrome c oxidase pathway (T2) receive direct input regardless of whether endogenous DIO1 conversion is functional. When rT3 is normal but the T3 plateau persists, moving from T3-alone supplementation to a T3+T2 combination approach is the logical next step in the T3-to-T2 conversion bottleneck framework.

Explanation 4: Adrenal Dysfunction / Low Cortisol

T3 is a catabolic activator. It elevates metabolic rate, increases mitochondrial thermogenesis, accelerates protein turnover, and raises the overall energy demand of peripheral tissues. These metabolic effects require substrate - the raw material that the elevated metabolism will consume. Cortisol is the primary catabolic substrate mobilizer: it drives gluconeogenesis, liberates fatty acids from adipose tissue, and provides the energetic supply chain that elevated thyroid hormone activity requires.

The research-community framework for the T3-cortisol interaction is often summarized as: T3 pushes the accelerator; cortisol provides the fuel. A research subject with inadequate cortisol output attempting to run a T3 protocol is, in mechanical terms, increasing engine demand without adequate fuel supply. The engine cannot respond appropriately.

The presentation of cortisol-deficiency T3 non-response is specific. Research subjects with low morning cortisol or a flat diurnal cortisol curve often report that T3 does not produce the expected energy response - or, more distinctively, that T3 makes them feel worse rather than better. Increased fatigue, worsening of low-blood-pressure symptoms, light-headedness, and a paradoxical worsening of cold intolerance despite increasing T3 dose are characteristic signals. The body is experiencing elevated metabolic demand from the T3 signal without the cortisol substrate to meet that demand.

The pattern can also present as T3 "wearing off" between doses faster than it should, or as an inability to sustain the temperature gains achieved during early titration. If cortisol availability fluctuates - as it does with the diurnal cortisol curve disruption common in chronic illness - T3 effectiveness may track cortisol status through the day rather than remaining stable between SR-T3 doses.

The lab evaluation for Explanation 4 is morning cortisol (ideally serum, drawn before 8 AM) or a 4-point salivary cortisol panel capturing the full diurnal curve. Research subjects in the bioenergetic research community typically target morning serum cortisol in the upper half of the reference range (roughly 15-25 mcg/dL) as an indicator of adequate adrenal reserve. A flat diurnal pattern - cortisol that does not rise appropriately in the early morning hours - is often more diagnostically informative than a single low morning value, because it reveals the circadian disruption of the cortisol rhythm rather than just a snapshot measurement.

For the full cortisol-T3 interaction framework, including how the two hormones interact at the receptor level and why chronically stressed research subjects often need to address adrenal function before T3 protocols become effective, see the T3 and adrenal fatigue cortisol connection guide. The diagnostic question for Explanation 4: have you measured AM cortisol, or run a 4-point salivary panel to assess the full diurnal pattern?

Explanation 5: Iron / Ferritin Deficiency

Iron occupies a specific and underappreciated role in thyroid hormone function that makes iron deficiency - particularly the subclinical low-ferritin state that standard clinical labs frequently miss - a significant source of T3 non-response.

Iron is required for thyroid peroxidase (TPO) activity. TPO is the enzyme that catalyzes the organification of iodide and the coupling reactions that produce T4 and T3 in the thyroid gland. In research subjects still producing endogenous thyroid hormone, iron deficiency directly impairs thyroid hormone synthesis at the source. This is a well-documented pathway: iron-deficiency anemia is associated with hypothyroid-like symptom presentations even in subjects with normal serum TSH, because the biosynthesis step is impaired upstream of everything TSH measures.

Beyond TPO synthesis, iron plays a role in thyroid hormone receptor binding affinity. The precise mechanism at this level is less completely characterized than the TPO pathway, but multiple case series have documented that iron repletion to adequate ferritin levels produces improvement in T3 hormone responsiveness that is not fully explained by TPO effects alone. The research community's working hypothesis is that iron deficiency impairs peripheral T3 receptor function through multiple pathways simultaneously.

The ferritin target used in the bioenergetic research community is materially different from the standard clinical reference range. Most laboratory reference ranges for ferritin bottom out at 12-15 ng/mL for women - a threshold calibrated to prevent overt iron-deficiency anemia, not to optimize thyroid hormone function. The research-community target for thyroid optimization is ferritin above 70 ng/mL, with many practitioners targeting 90-100 ng/mL. Research subjects with ferritin measured at 30-40 ng/mL will typically be told by a standard lab report that their iron is normal. The bioenergetic research framework considers ferritin in this range substantially suboptimal for T3 protocol effectiveness.

The practical consequence: a research subject with ferritin at 35 ng/mL attempting a T3 protocol may see minimal response regardless of dose adequacy, rT3 status, or cortisol function, simply because the iron-dependent steps of thyroid hormone receptor function are compromised. Iron repletion - typically via oral iron supplementation, with recheck of ferritin at 6-8 weeks - often resolves the apparent T3 non-response without requiring any change to the T3 protocol itself.

The diagnostic question for Explanation 5: has ferritin been measured and confirmed above 70 ng/mL? If not, this should be evaluated before assuming the T3 protocol requires adjustment.

Explanation 6: Autoimmune Flare

Research subjects with Hashimoto's thyroiditis introduce a complicating variable that is absent in non-autoimmune hypothyroid presentations: active immune-mediated tissue attack on the thyroid gland, which drives a chronic inflammatory state independent of thyroid hormone levels.

The T3 non-response pattern from autoimmune flare is mechanistically distinct from the other five explanations. In Explanations 1-5, the T3 itself is the variable - the dose is wrong, the receptors are blocked, the downstream conversion is impaired, the substrate supply is deficient. In Explanation 6, T3 may be adequately dosed, adequately converted, adequately received at the receptor - but the chronic symptom picture persists because the autoimmune attack itself is driving fatigue, cognitive impairment, joint pain, and the other manifestations of chronic illness that prompted the T3 protocol in the first place. T3 cannot resolve symptoms caused by an ongoing immune-mediated inflammatory process, regardless of dose.

Hashimoto's flares can be triggered by multiple inputs: dietary gluten exposure in subjects with thyroid-specific anti-gliadin reactivity, iodine excess, viral infection, psychological stress, and disruptions to intestinal barrier function. During an active flare, thyroid peroxidase antibodies (TPO-Ab) and thyroglobulin antibodies (TgAb) typically rise, and systemic inflammatory markers may elevate alongside them. The inflammatory load from the flare competes with and often overwhelms whatever T3 signaling is occurring.

The diagnostic signal for Explanation 6 is the clinical context: does the T3 non-response correlate with other Hashimoto's symptoms? Increased joint pain, increased brain fog, worsened gut symptoms, skin manifestations, and elevated TPO antibodies on labs all point toward an autoimmune flare as the primary driver. Research subjects who have previously responded to T3 protocols and then lose that response without changing the protocol or dose are particularly likely to be experiencing a flare-driven loss of effectiveness rather than a pharmacological T3 non-response.

The research-community approach to T3 non-response in Hashimoto's is to address the autoimmune driver first - identify and eliminate dietary triggers, address intestinal permeability, manage psychological stressors, and stabilize antibody levels - before escalating T3 dose or changing the protocol structure. For the full framework of T3 supplementation in the context of Hashimoto's, including how TPO antibody patterns interact with T3 effectiveness, see the Hashimoto's T3 supplementation guide.

The Diagnostic Framework: Which Explanation Applies to You

The six explanations are not mutually exclusive. Multiple explanations can co-exist in the same research subject, and the resolution of one often reveals the presence of another. The research-community framework for working through them follows a rough sequential logic, moving from simplest to most complex.

Step 1: Dose adequacy. Before investigating any of the mechanism-based explanations, confirm that the T3 dose has been meaningfully titrated. If the research subject is on 15-22.5 mcg/day with no adverse effects and no temperature response, the dose has not been adequately tested. Titrate in standard Wilson's increments to at least 45 mcg/day or to clear adverse effects before concluding that dose is not the explanation.

Step 2: rT3 check. If titration has reached meaningful doses and temperature response is absent or inadequate, measure the FT3:rT3 ratio. An FT3:rT3 ratio below 20 confirms rT3 dominance as a contributing factor. The WT3 cyclic approach targets rT3 clearance specifically; if rT3 is elevated, the protocol's dose-escalation and suppression structure is the appropriate response.

Step 3: T3-to-T2 conversion assessment. If rT3 has been normalized (or was never elevated) and the T3 plateau persists with free T3 in adequate range and temperature below target, the T3-to-T2 conversion bottleneck is the most likely mechanism. This is the explanation that does not appear on standard thyroid panels - free T3 looks fine, rT3 looks fine, TSH is suppressed - but metabolic underperformance continues because the mitochondrial pathway is not receiving adequate T2. The corrective step here is moving from SR-T3 alone to a T3+T2 combination protocol. The Wilson's T3+T2 Combo provides T3 and T2 at a 1:1 ratio in sustained-release form, bypassing the conversion bottleneck directly. For the full sustained-release T3 foundation underlying this step, see the sustained-release T3 complete guide. For the combined product protocol structure, see the Wilson's SR-T3 Combo for pure SR-T3, or the Wilson's T3+T2 Combo for the conversion-bottleneck-targeted combination.

Step 4: Cortisol assessment. If T3 dose is adequate, rT3 is normalized, and T2 supplementation has been added without resolving the plateau, check morning cortisol or a 4-point salivary panel. Low cortisol or flat diurnal pattern impairs the metabolic substrate supply required for T3 to perform its catabolic functions.

Step 5: Iron/ferritin check. Ferritin below 70 ng/mL warrants iron repletion before drawing any conclusions about T3 protocol effectiveness. This is a simple, resolvable variable that is frequently overlooked because standard labs report low-normal ferritin as "normal."

Step 6: Autoimmune status. In Hashimoto's subjects, correlate T3 non-response with antibody levels and symptom patterns. An active flare requires addressing the immune driver, not escalating the T3 dose.

This sequential framework is the reference decision tree used in research-community troubleshooting discussions. It does not require working through all six steps in every case - many research subjects will identify the correct explanation at Step 1 or Step 2. But having the full framework prevents the common error of jumping directly from "T3 isn't working" to maximum dose escalation without investigating the mechanism.

What Research Has and Hasn't Established

Established:

The foundational mechanisms underlying each of the six explanations are well-characterized in the peer-reviewed literature. Deiodinase enzymology - DIO1, DIO2, and DIO3 functions, selenoprotein cofactor requirements, inflammatory suppression of DIO activity - is documented across multiple decades of research. Reverse T3 dominance as a receptor-competitive mechanism is characterized in the thyroid hormone literature. The T3-cortisol axis interaction - specifically, that T3 elevates metabolic demand and that cortisol provides the catabolic substrate for elevated metabolism - is established through multiple lines of animal-model and clinical evidence. Iron is required for thyroid peroxidase activity and ferritin is documented as a marker for thyroid hormone optimization adequacy in case series. Selenium is a confirmed cofactor for the entire deiodinase family, with deficiency impairs conversion documented in both animal models and clinical observations. 3,5-T2 binds cytochrome c oxidase subunit Va and produces mitochondrial effects that T3 does not replicate via genomic pathways - established by the 1994 Goglia et al. paper and supported by subsequent rodent-model literature.

Hypothesis:

The six-explanation diagnostic framework as a complete, ordered decision tree for T3 non-response is a research-community construct - mechanistically coherent, broadly discussed and applied in thyroid research forums and practitioner networks, but not validated as a unified protocol in randomized controlled trial design. The T3-to-T2 conversion bottleneck as a distinct clinical entity explaining the specific plateau pattern of adequate free T3 with persistent metabolic underperformance is the framework component with the strongest mechanistic foundation and the least direct clinical validation. The individual mechanisms are established; the integrated diagnostic use of them as a decision sequence has not been formally tested against placebo-controlled comparators.

Not endorsed by mainstream endocrinology:

The entire bioenergetic research-community diagnostic framework for T3 non-response operates outside mainstream endocrinology guidelines. Mainstream endocrinology does not recognize Wilson's Temperature Syndrome as a formal diagnosis, does not use basal body temperature as a treatment endpoint, does not endorse T3-only or T3-dominant protocols for most hypothyroid presentations, and does not include T2 supplementation in any clinical guideline. The multi-factor framework described in this article - treating T3 non-response as a diagnostic investigation rather than simply adjusting TSH targets - represents research-community theory that is mechanistically grounded but clinically unvalidated according to current endocrinological standards. Researchers working within this framework should apply appropriate experimental rigor, monitoring, and caution consistent with working at the frontier of a field that mainstream medicine has not yet formally characterized.

Frequently Asked Questions

Why isn't my T3 working?

T3 non-response has six distinct mechanism-based explanations in the bioenergetic research community: insufficient dose (below the threshold that produces the temperature endpoint), reverse T3 dominance (rT3 competing at receptor sites), the T3-to-T2 conversion bottleneck (DIO1 impairment preventing T3 from reaching the mitochondrial pathway), adrenal dysfunction (insufficient cortisol to provide the metabolic substrate T3 needs), iron/ferritin deficiency (iron required for thyroid peroxidase and receptor function), and autoimmune flare (Hashimoto's tissue-level inflammation independent of T3 signaling). Working through the diagnostic framework in sequence identifies which explanation applies.

What are the most common reasons T3 stops working?

The most frequently encountered explanations in research-community discussion are dose insufficiency (research subjects stopping titration before reaching the dose that actually produces the target response) and reverse T3 dominance (rT3 accumulation blocking receptor binding). The T3-to-T2 conversion bottleneck is increasingly recognized as a third major explanation, particularly in subjects who have cleared rT3 dominance but plateau below the temperature target despite adequate free T3 on serum panels. Low cortisol and low ferritin are supporting factors that frequently co-exist with the primary explanations.

How do I know if I have reverse T3 dominance?

The diagnostic test for reverse T3 dominance is measurement of the FT3:rT3 ratio. A ratio below 20 (with FT3 in pg/mL and rT3 in ng/dL) indicates rT3 dominance by the most commonly used research-community threshold. The clinical signal is adequate-to-high serum free T3 with no corresponding symptom improvement - T3 measurably present but not producing effects, because rT3 is occupying receptor sites. Standard TSH and free T3 panels do not detect rT3 dominance; rT3 must be directly measured.

What is the T3 to T2 conversion bottleneck?

The T3-to-T2 conversion bottleneck is the hypothesis that DIO1 deiodinase dysfunction - the same deiodinase impairment that blocks T4-to-T3 conversion in the first place - also impairs the downstream conversion of T3 to 3,5-T2 (3,5-diiodothyronine). Since 3,5-T2 operates through the mitochondrial cytochrome c oxidase pathway (distinct from T3's nuclear receptor pathway), a research subject with intact T3 at the receptor but impaired T3-to-T2 conversion will have adequate genomic signaling but deficient mitochondrial activation. The conversion bottleneck produces a characteristic plateau pattern: adequate free T3, normalized rT3, suppressed TSH, but body temperature stalling below 98.6°F and persistent fatigue that additional T3 dose does not resolve.

Can low cortisol cause T3 to stop working?

Yes. T3 elevates metabolic demand throughout peripheral tissues; cortisol provides the catabolic substrate (glucose, fatty acids) that the elevated metabolism requires. Research subjects with low morning cortisol or a flat diurnal cortisol curve often find that T3 produces no benefit or even worsening - because the metabolic demand from T3 exceeds the available substrate supply. The interaction can also present as T3 effects that fade between doses, or temperature gains during titration that cannot be sustained. Morning serum cortisol or a 4-point salivary cortisol panel is the appropriate diagnostic evaluation.

Does low ferritin block T3 from working?

Yes. Iron is required for thyroid peroxidase (TPO) activity and contributes to thyroid hormone receptor responsiveness. The bioenergetic research community targets ferritin above 70 ng/mL for thyroid optimization - substantially above the standard clinical reference-range minimum of 12-15 ng/mL. Research subjects with ferritin in the 20-50 ng/mL range are frequently told by standard labs that their iron is normal, while experiencing thyroid hormone non-response attributable to iron-deficiency impairment of thyroid function. Ferritin repletion to above 70 ng/mL commonly resolves T3 non-response without any change to the T3 protocol.

Should I increase my T3 dose if it stops working?

Not automatically - the answer depends on which of the six explanations is driving the non-response. If the dose has never been adequately titrated, increasing it is the correct first step. If rT3 dominance is confirmed, dose escalation within the Wilson's WT3 framework is appropriate. If rT3 is normal and free T3 is adequate but the plateau persists, adding more T3 will not resolve a T3-to-T2 conversion bottleneck - the correct response is adding T2 supplementation directly. If low cortisol is the driver, escalating T3 dose without addressing adrenal function may worsen the substrate-demand mismatch. The diagnostic framework determines which intervention is appropriate; dose escalation is one tool in the framework, not the automatic response to any non-response pattern.

When should I switch from T3 alone to T3+T2?

The research-community indication for moving from SR-T3 alone to a T3+T2 combination is the specific plateau pattern that characterizes the T3-to-T2 conversion bottleneck: adequate serum free T3, normalized or never-elevated rT3, TSH suppressed by the T3 protocol, but body temperature plateauing below 98.6°F and persistent metabolic underperformance that does not respond to further T3 dose increases. This pattern suggests that the nuclear receptor pathway is adequately served by the existing T3, but the mitochondrial cytochrome c oxidase pathway is not receiving adequate T2 because DIO1-mediated conversion is impaired. The Wilson's T3+T2 Combo is the reference product for this research application, providing T3 and T2 at a 1:1 ratio in sustained-release form.

Closing Note

T3 non-response is not a single problem. It is a diagnostic category that encompasses six distinct mechanism-based explanations, each with a different root cause, a different lab signature, and a different corrective approach. The research-community value of the six-explanation framework is that it prevents the most common error in T3 troubleshooting: treating non-response as a single-variable problem and cycling through dose escalations without investigating the mechanism.

For research subjects working through an SR-T3 protocol that is not producing the expected response, the SR-T3 dosing troubleshooting complete guide covers the full diagnostic and titration framework in depth, including the temperature tracking protocol, the adverse effect monitoring structure, and how each of the six non-response mechanisms presents in the context of active titration. For research subjects whose troubleshooting investigation points toward the T3-to-T2 conversion bottleneck, the Wilson's T3+T2 Combo provides the combined T3+T2 supplementation format designed to bypass the impaired conversion step. The full catalog of thyroid research compounds is available for researchers evaluating the full range of options.